Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: GlobeNewswire
Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow with extended treatment (PUL v2.0)Deramiocel’s long-term safety profile remains favorableResults presented at PPMD’s 2025 Annual Conference SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be featured in the session titled “Therapies that Slow Progression” at the Parent Project Muscular Dystrophy (PPMD) 2025 Annual Conference, taking place June 21, 2025, in Las Vegas, Nevada. After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to basel
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmBusiness Wire
- Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class ActionGlobeNewswire
- INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics, Inc. (CAPR) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmGlobeNewswire
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Capricor Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of September 15, 2025GlobeNewswire
- BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover LossesGlobeNewswire
CAPR
Earnings
- 5/13/25 - Miss
CAPR
Sec Filings
- 7/11/25 - Form 8-K
- 6/16/25 - Form S-8
- 5/27/25 - Form 8-K
- CAPR's page on the SEC website